Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1994 1
1995 1
1998 2
1999 1
2000 1
2001 4
2002 5
2003 4
2004 1
2005 6
2006 4
2007 1
2008 4
2010 1
2011 6
2012 3
2013 4
2014 3
2015 3
2016 3
2017 3
2018 3
2019 3
2020 6
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

69 results
Results by year
Filters applied: . Clear all
Page 1
[A cross sectional study on patients with inflammatory rheumatic diseases in terms of their compliance to their immunsuppressive medication during COVID-19 pandemic].
Schmeiser T, Broll M, Dormann A, Fräbel C, Hermann W, Hudowenz O, Keil F, Müller-Ladner U, Özden F, Pfeiffer U, Saech J, Schwarting A, Stapfer G, Steinchen N, Storck-Müller K, Strunk J, Thiele A, Triantafyllias K, Wassenberg S, Wilden E, Hasseli R. Schmeiser T, et al. Among authors: wassenberg s. Z Rheumatol. 2020 May;79(4):379-384. doi: 10.1007/s00393-020-00800-8. Z Rheumatol. 2020. PMID: 32303821 Free PMC article. German.
Golimumab as the First-, Second-, or at Least Third-Line Biologic Agent in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis: Post Hoc Analysis of a Noninterventional Study in Germany.
Krüger K, Burmester GR, Wassenberg S, Thomas MH. Krüger K, et al. Among authors: wassenberg s. Rheumatol Ther. 2020 Jun;7(2):371-382. doi: 10.1007/s40744-020-00204-9. Epub 2020 Apr 17. Rheumatol Ther. 2020. PMID: 32303994 Free PMC article.
Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman D, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen J. Antoni CE, et al. Among authors: wassenberg s. Arthritis Rheum. 2005 Apr;52(4):1227-36. doi: 10.1002/art.20967. Arthritis Rheum. 2005. PMID: 15818699 Free article. Clinical Trial.
[S2e guideline: treatment of rheumatoid arthritis with disease-modifying drugs].
Fiehn C, Holle J, Iking-Konert C, Leipe J, Weseloh C, Frerix M, Alten R, Behrens F, Baerwald C, Braun J, Burkhardt H, Burmester G, Detert J, Gaubitz M, Gause A, Gromnica-Ihle E, Kellner H, Krause A, Kuipers J, Lorenz HM, Müller-Ladner U, Nothacker M, Nüsslein H, Rubbert-Roth A, Schneider M, Schulze-Koops H, Seitz S, Sitter H, Specker C, Tony HP, Wassenberg S, Wollenhaupt J, Krüger K. Fiehn C, et al. Among authors: wassenberg s. Z Rheumatol. 2018 Aug;77(Suppl 2):35-53. doi: 10.1007/s00393-018-0481-y. Z Rheumatol. 2018. PMID: 29968101 Review. German.
Scoring methods.
Rau R, Wassenberg S. Rau R, et al. Among authors: wassenberg s. J Rheumatol. 2002 Apr;29(4):653-5. J Rheumatol. 2002. PMID: 11950002 Review. No abstract available.
69 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page